Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Standard hepatitis B therapy].

G Gerken1

  • 1Abteilung für Gastroenterologie und Hepatologie, Universitätsklinik Essen.

Praxis
|October 3, 2000
PubMed
Summary
This summary is machine-generated.

Standard treatments for chronic hepatitis B virus (HBV) infection include interferon-alpha and nucleoside analogues. While interferon is effective for some, nucleoside analogues offer a viable option for advanced liver disease and non-responders, though long-term outcomes require further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender and gut microbiota composition determine hepatic bile acid, metabolic and inflammatory response to a single fast-food meal in healthy adults.

Clinical nutrition (Edinburgh, Scotland)·2021
Same author

Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.

Journal of cancer research and clinical oncology·2018
Same author

Effects of the Mammalian Target of Rapamycin Inhibitor Everolimus on Hepatitis C Virus Replication In Vitro and In Vivo.

Transplantation proceedings·2017
Same author

Microarrays-Enabled Hypothesis Generation: The Suspect Role of FNBP-1 in Neuropsychiatric Pathogenesis Associated with HIV and/or HCV Infection.

Journal of AIDS & clinical research·2017
Same author

[Obeticholic acid in primary biliary cholangitis : PBC OCA international study of efficacy (POISE)].

Der Internist·2017
Same author

[Hepatology 2017: from basics to clinics - future perspectives].

Zeitschrift fur Gastroenterologie·2016
Same journal

Praxis·2026
Same journal

[What do Swiss doctors think about cardiovascular risk factors and guidelines?]

Praxis·2026
Same journal

[Laser interstitial thermotherapy (LITT): a minimally invasive neurosurgical treatment option for brain tumours and radiation necrosis].

Praxis·2026
Same journal

[Persistent back pain after lifting trauma. From the trivial to the rare case].

Praxis·2026
Same journal

[A patient with dizziness and gait instability - a diagnostic challenge].

Praxis·2026
Same journal

[Meningoencephalitis caused by listeria monocytogenes].

Praxis·2026
See all related articles

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Context:

  • Chronic hepatitis B virus (HBV) infection management relies on interferon-alpha and nucleoside analogues.
  • Interferon-alpha achieves 30-50% seroconversion in specific patient groups (hepatic inflammatory activity, low viral titers, HBe-positive wild-type).
  • Advanced liver disease, interferon non-responders, and HBe-negative mutants present treatment challenges.

Purpose:

  • To evaluate the efficacy of antiviral nucleoside analogues as an alternative treatment for chronic HBV infection.
  • To assess the long-term outcomes of nucleoside analogue therapy.
  • To investigate the emergence of HBV polymerase gene mutants during treatment.

Summary:

  • Nucleoside analogues, such as lamivudine, are a clinically proven therapeutic option for patients with advanced liver disease, interferon non-responders, and HBe-negative HBV mutants.

Related Experiment Videos

  • Standard interferon-alpha treatment yields moderate long-term seroconversion rates in select HBV patients.
  • The long-term efficacy and potential for viral resistance, specifically HBV polymerase gene mutations, require further investigation.

    • Impact:

    • Provides insights into alternative treatment strategies for chronic hepatitis B.
    • Highlights the need for continued research into long-term outcomes and resistance mechanisms of antiviral therapies.
    • Informs clinical decision-making for managing difficult-to-treat chronic HBV cases.